Journal
AUTOIMMUNITY REVIEWS
Volume 18, Issue 11, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.autrev.2019.102390
Keywords
JAK inhibitor; Autoimmune disease; Rheumatoid arthritis; Psoriatic arthritis; Tofacitinib
Categories
Ask authors/readers for more resources
y Cytokines play a central role in the pathophysiology of autoimmune and inflammatory diseases. Several cytokines signal through the JAK-STAT pathway, which is now recognized as a major target to inhibit the effect of a wide array of cytokines. JAK inhibitors are increasingly used in the setting of inflammatory and autoimmune diseases. While the currently approved drugs are panJAK inhibitors, more selective small molecules are being developed and tested in various rheumatic disorders. In this extensive review, we present evidence- or hypothesis-based perspectives for these drugs in various rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, and autoinflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available